Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspirin + clopidogrel + statins is a therapeutic combination regimen frequently referred to as optimal medical therapy (OMT) for the secondary prevention of cardiovascular events in patients with coronary heart disease (CHD). This regimen combines two antiplatelet agents with a lipid-lowering agent. **Aspirin** irreversibly inhibits cyclooxygenase-1 (COX-1), thereby preventing the synthesis of thromboxane A2 and inhibiting platelet aggregation. **Clopidogrel** is a thienopyridine that acts as a selective and irreversible antagonist of the P2Y12 ADP receptor on platelets, providing a complementary mechanism for preventing thrombus formation. **Statins** (HMG-CoA reductase inhibitors) lower LDL cholesterol by inhibiting the rate-limiting enzyme in cholesterol biosynthesis and offer pleiotropic benefits such as plaque stabilization and anti-inflammatory effects. In the context of clinical research at The First Affiliated Hospital with Nanjing Medical University, this combination serves as the standard pharmacological baseline for evaluating the efficacy of individualized exercise training based on cardiopulmonary exercise testing (CPET) in elderly patients with CHD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + clopidogrel + statins.